A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients (GEM-1)
A Phase I/II Study of KB103, a Non-Integrating, Replication-Incompetent HSV Vector Expressing the Human Collagen VII Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
Sponsor: Krystal Biotech, Inc.
A PHASE1/PHASE2 clinical study on Dystrophic Epidermolysis Bullosa, this trial is completed. The trial is conducted by Krystal Biotech, Inc. and has accumulated 9 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed · Phase: PHASE2 → PHASE1_PHASE2
-
Oct 2021 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 4 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2019 — Apr 2020 [monthly]
Recruiting PHASE2
-
Nov 2018 — Feb 2019 [monthly]
Recruiting PHASE2
Phase: PHASE1_PHASE2 → PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
May 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Krystal Biotech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .